Jun 25 2019
MSCO and Kiang Wu Hospital Oncology Image Seminar was held on 2019-5-18 at Macau. Attendance came form China mainland, HK, Taiwan and Macau. There were 4 sections in the seminar, focus on prostate cancer, breast cancer, lung cancer and lymphoma. In each section, speakers talks about recent progress in disease specific image characteristics, advance in […]
Jun 25 2019
Nature 2019 May; 569(7756) Immunotherapy combined with PD-1 and CTLA-4 is effective for renal melanoma and non-small cell lung cancer.However, thiscomes at the cost of frequent, serious immune-related adverseevents, necessitating a reduction in the recommended dose ofipilimumab that is given to patients. Immune-related adverse events that result from therapy with checkpoint inhibitors are usually satisfactorily treated […]
Jun 25 2019
Lee Schwartzberg,Beata Korytowsky,John R. Penrod,Ying Zhang, T. Kim Le,Cory Batenchuk, Lee Kru Lung cancer is the first most common malignancy in the wild word, and the leading cause of cancer-related mortality. Approximately 85% of lung cancers are non-small-cell lung cancer (NSCLC). More than half of all lung cancers in the United States are diagnosed at […]
Apr 11 2019
On December 8, 2019. MSCO held a MTD meeting with team for 6th Affiliated hospital of Sun Yet-sen university (Guangzhou), 5th Affiliated hospital of Sun Yet-sen university (Zhuhai) and Cancer centre of Sun Yet-sen university (Guangzhou). Several cases were discussed in the meeting, regard the treatment sequence of chemo and operation procedure. Use of IO […]
Apr 11 2019
On March 23, MSCO held a conference on Immuno- Oncology in MGM. Experts from China and Macau were joined and shared their opinions on this hot topic. Two IO drugs has been licensed in China and patients can get assess to IO treatment more easily than before. However many issues were now became more and […]
Mar 8 2019
Dr. Best S A et al recently report their finding on NSCLC and KEAP1/NRF2 and PI3K Pathways[1]. It is well known that non-small cell lung cancer is the most common type of lung cancer, with a lower survival rate in most cancer.Adenocarcinoma (ADC) is the major histological subtype of lung cancer and the KEAP1/NRF2 pathway […]
Mar 8 2019
Recently Dr. Mainardi S, et al. found SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer. Research published at Nature Medicine on May 28, 2018. Lung cancer is the most common cause of cancer death worldwide, about 1.6 million deaths every year. Non-small cell lung cancer (NSCLC) is the primary type of lung cancer […]
Mar 8 2019
Recently, Dr. Takeshi Tanoue et al report relationship between CD8 T-cells and anti-cancer immunity. This paper was published on Nature volume 565, pages600–605 (2019) Dysbiosis of commensal microbiota can contribute to cancer onset, progression and therapy response through effects on anti-tumor immunity1-4.The currently studies have now advanced our understanding of local microbiota immunomodulation and gaveustheinsight into the potential of […]
Dec 22 2018
2018 Member meeting of MSCO was held on Sep 29, 2018. During this meeting many important issues were voted for approve, regarding financial and regulations on management.
Apr 11 2019
Elaine’s group discovered a cardiac glycoside restrains EGFR-related and EGFR-independent NSCLC cell proliferation with distinct treatment mechanism
Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer and is characterized by the highest mortality and incidence rates among these types of malignancies (1, 2). Traditional Chinese medicine (TCM) has been applied for centuries in China (3, 4). Cardiac glycosides, a class of natural products, have been identified as a […]
Read More
By Yabing • News, Research • 0